Pure Global AI
NCT06294639Not yet recruiting

ED50 of Esketamine for Laser Treatment in Children

Median Effective Dose (ED50) of Esketamine Combined With Alfentanil for Children to Inhibit Body Movement During Laser Treatment for Facial Lesion
Air Force Military Medical University, ChinaClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Anesthesia
Drug/Device/Intervention
Esketamine
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Air Force Military Medical University, China
Timeline & enrollment
Phase
N/A
Start date
Mar 27, 2024
End date
Apr 27, 2025
Enrollment
40 participants
Primary outcome

half effective dose of inhibition of body movement

Summary

There is limited research on the combined use of esketamine and alfentanil for anesthesia
 during facial laser treatment in pediatric patients, and the effective dosage of esketamine
 for inhibiting body movement remains unclear. We explore the effective dose of esketamine
 combined with alfentanil for the inhibition of body movement during facial laser treatment in
 pediatric patients.

ICD-10 classifications
Anaesthetic, unspecifiedOther and unspecified general anaestheticsLocal anaestheticsOther complications of anaesthesiaComplication of anaesthesia during labour and delivery, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06294639
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06294639 through Pure Global AI's free database. This phase not specified trial is sponsored by Air Force Military Medical University, China and is currently Not yet recruiting. The study focuses on Anesthesia. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.